• Press Office

    Posted in category News Release by Press Office on 14/05/2014

    ABPI comment on the Concordat on Openness on Animal Research

Commenting on today’s launch of the Concordat on Openness on Animal Research, Dr Louise Leong, Director of Research & Development Policy at the ABPI, said:


“The launch of the Concordat on Openness on Animal Research is a significant milestone which confirms a commitment from those sectors involved in animal research, including the pharmaceutical industry, to achieve greater openness and transparency on this important issue. Our commitment to the Concordat is recognition that our industry has a duty to demonstrate and promote our values and to be open, transparent and accountable for the research that we conduct, fund and support.  

“If we are going to truly change the perception and public opinion on animal research we need to be able to show its benefits and to educate and inform the public about the necessity of our work, which the Concordat helps us to do.  This includes the pharmaceutical industry’s role in the development of 90% of the medicines in the world, and the fact that, without vital research using animals, there are many diseases - such as epilepsy and diabetes - which could not be managed the way they are today.”


Notes to editor

The ABPI, along with 10 member companies, have signed the Concordat. The companies are:  

  • ABPI
  • Astra Zeneca
  • Charles Rivers Preclinical Services
  • Covance
  • GlaxoSmithKline
  • Harlan Laboratories
  • Huntingdon Life Sciences
  • Lilly UK
  • Pfizer
  • Sequani
  • UCB

About the ABPI

The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.  

Media enquiries

ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811
Print this page icon Print this page
Please choose the subject of your enquiry from the list below:
Code to enter for submitting the form
Enter the above code here:
Can't read? Try different words.